The health economics of chemoprevention for breast cancer in Australia

Bonny Parkinson, James F. Bishop, Parisa Glass, Lynne Pezzullo, Peter Moore, Trish Cotter, Elizabeth A Tracey

Research output: Book/ReportCommissioned report

Abstract

This report assesses the economic impact of the introduction of raloxifene and/​or tamoxifen to prevent breast cancer in Australia. The report models the cost-effectiveness of both drugs when used as chemopreventive agents compared with no treatment.
Original languageEnglish
Place of PublicationSydney, N.S.W.
PublisherCancer institute NSW
Commissioning bodyCancer Institute NSW
Number of pages149
ISBN (Electronic)9781741872033
Publication statusPublished - Jun 2008
Externally publishedYes

Publication series

NameCancer Institute NSW monograph

Keywords

  • chemoprevention
  • tamoxifen
  • raloxifene
  • Herceptin breast cancer
  • uterine cancer
  • Australia

Fingerprint Dive into the research topics of 'The health economics of chemoprevention for breast cancer in Australia'. Together they form a unique fingerprint.

  • Cite this

    Parkinson, B., Bishop, J. F., Glass, P., Pezzullo, L., Moore, P., Cotter, T., & Tracey, E. A. (2008). The health economics of chemoprevention for breast cancer in Australia. (Cancer Institute NSW monograph). Sydney, N.S.W.: Cancer institute NSW.